Jump to content
RemedySpot.com

vagal nerve stimulation

Rate this topic


Guest guest

Recommended Posts

The Pubmed search

vagus AND nerve AND stimulation AND (seizur* OR epileptiform)

today generated 341 cites.

The first 20 or so were surprisingly on target. Here they are. Many of

the next 321 are probaby peachy keen too.

*1: *Eur J Paediatr Neurol. <javascript:AL_get(this, 'jour', 'Eur J

Paediatr Neurol.');> 2005 Oct 27; [Epub ahead of print] Related

Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16257548>

Links <javascript:PopUpMenu2_Set(Menu16257548);>

*Beneficial effects on sleep of vagus nerve stimulation in children

with therapy resistant epilepsy.*

*Hallbook T*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Hall\

book+T%22%5BAuthor%5D>,

*Lundgren J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Lund\

gren+J%22%5BAuthor%5D>,

*Kohler S*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Kohl\

er+S%22%5BAuthor%5D>,

*Blennow G*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Blen\

now+G%22%5BAuthor%5D>,

*Stromblad LG*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Stro\

mblad+LG%22%5BAuthor%5D>,

*Rosen I*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Rose\

n+I%22%5BAuthor%5D>.

Department of Paediatrics, University Hospital, SE-221 85 Lund, Sweden.

The study purpose was to evaluate sleep structure following Vagus

Nerve Stimulation (VNS) in 15 children with therapy resistant

epilepsy and to correlate possible alterations with changes in

epileptiform activity and clinical effects. Fifteen children were

examined with ambulatory polysomnographic recordings initially, and

after 3 and 9 months of VNS-treatment. Sleep parameters, all-night

delta power activity and movement times (MTs), used to account for

arousals were estimated. Epileptiform activity was evaluated by

spike detection. Seizure frequency was recorded in a diary. The

severity of the seizures was scored with the National Hospital

Seizure Severity Scale (NHS3). Quality of life (QOL) was assessed by

a visual analogue scale. Behaviour problems were quantified by using

the total score of the Child Behaviour Checklist (CBCL). VNS induces

a significant increase in slow wave sleep (SWS) and a decrease in

sleep latency and in stage 1 sleep. The number and density of MTs

during total night sleep were significantly increased. There was

also a significant increase in the number of MTs immediately related

to the VNS stimulation periods. Of the 14 children with increased

MTs, 10 had a reduction in epileptiform activity, and in clinical

seizures, all had an improvement in NHS3, and 11 in QOL. Of the 10

children with increased SWS, eight also improved in QOL and eight in

behaviour. Our findings indicate that VNS counteracts known adverse

effects of epilepsy on sleep and increases slow wave sleep. This

possibly contributes to the reported improvement in well-being. We

also see an increase in MTs. This arousal effect seems to be of

minor importance for QOL and could possibly be related to the

antiepileptic mechanisms in VNS.

PMID: 16257548 [PubMed - as supplied by publisher]

------------------------------------------------------------------------

*2: *Seizure. <javascript:AL_get(this, 'jour', 'Seizure.');> 2005

Oct;14(7):504-13. Epub 2005 Sep 19. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16176878>

Links <javascript:PopUpMenu2_Set(Menu16176878);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048 & uid=16176878 & db=\

pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S1059-1311%2805%2900150-0\

>

*Vagus nerve stimulation in 15 children with therapy resistant

epilepsy; its impact on cognition, quality of life, behaviour and mood.*

*Hallbook T*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Hall\

book+T%22%5BAuthor%5D>,

*Lundgren J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Lund\

gren+J%22%5BAuthor%5D>,

*Stjernqvist K*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Stje\

rnqvist+K%22%5BAuthor%5D>,

*Blennow G*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Blen\

now+G%22%5BAuthor%5D>,

*Stromblad LG*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Stro\

mblad+LG%22%5BAuthor%5D>,

*Rosen I*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Rose\

n+I%22%5BAuthor%5D>.

Department of Paediatrics, University Hospital, SE-221 85 Lund,

Sweden. tove.hallbook@...

PURPOSE: Vagus nerve stimulation (VNS) is a neurophysiologic

treatment for patients with refractory epilepsy. There is growing

evidence of additional quality of life (QOL) benefits of VNS. We

report the effects of VNS on seizure frequency and severity and how

these changes are related to cognitive abilities, QOL, behaviour and

mood in 15 children with medically refractory and for surgery not

eligible epilepsy. METHODS: Initially, and after 3 and 9 months of

VNS-treatment, 15 children were investigated with Bayley Scales of

Infant Development (BSID), Wechsler Preschool and Primary Scale of

Intelligence (WPPSI-R), Wechlser Intelligence Scales for Children

(WISC-III) depending on the child's level of functioning, a Visual

Analogue Scale for validating QOL, Child Behaviour Checklist (CBCL)

for quantifying behaviour problems, Dodrill Mood Analogue Scale and

Birleson Depression Self-Rating Scale, and the National Hospital

Seizure Severity Scale (NHS3). A diary of seizure frequency was

collected. RESULTS: Six of 15 children showed a 50% or more

reduction in seizure frequency; one of these became seizure-free.

Two children had a 25-50% seizure reduction. Two children showed

increased seizure frequency. In 13 of 15 children there was an

improvement in NHS3. The parents reported shorter duration of

seizure and recovery phase. There were no changes in cognitive

functioning. Twelve children showed an improvement in QOL. Eleven of

these also improved in seizure severity and mood and five also in

depressive parameters. CONCLUSION: This study has shown a good

anti-seizure effect of VNS, an improvement in seizure severity and

in QOL and a tendency to improvement over time regarding behaviour,

mood and depressive parameters. The improvement in seizure severity,

QOL, behaviour, mood and depressive parameters was not related to

the anti-seizure effect.

PMID: 16176878 [PubMed - in process]

------------------------------------------------------------------------

*3: *Neuroimmunomodulation. <javascript:AL_get(this, 'jour',

'Neuroimmunomodulation.');> 2005;12(5):307-9. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16166810>

Links <javascript:PopUpMenu2_Set(Menu16166810);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3030 & uid=16166810 & db=\

pubmed & url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext & file=N\

IM2005012005307>

*The effects of vagus nerve stimulation on pro- and

anti-inflammatory cytokines in humans: a preliminary report.*

*Corcoran C*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Corc\

oran+C%22%5BAuthor%5D>,

*Connor TJ*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Conn\

or+TJ%22%5BAuthor%5D>,

*O'Keane V*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22O%27\

Keane+V%22%5BAuthor%5D>,

*Garland MR*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Garl\

and+MR%22%5BAuthor%5D>.

Department of Psychiatry, Beaumont Hospital, and Royal College of

Surgeons in Ireland, Dublin, Ireland.

OBJECTIVE: Vagus nerve stimulation (VNS) is a novel therapy in

resistant epilepsy, and is undergoing clinical trials in resistant

depression. The mechanism of action of VNS is assumed to be due to

modulation of deep brain structures via its afferent connections. As

the vagus nerve has potentially important immunological actions that

may have relevance to its therapeutic effects, we hypothesised that

an additional mechanism may occur via vagally mediated actions on

cytokine synthesis. METHODS: Patients (n=10) with resistant

depression were studied in the weeks prior to, and 3 months

following, implantation of a vagus nerve stimulator. No medication

changes were made during the course of the study. High-sensitivity

ELISA kits were used to measure plasma IL-1 beta, IL-6, TNF-alpha,

IL-10 and TGF-beta concentrations. C-reactive protein (CRP) was

measured using a high sensitivity immunonephelometry assay. RESULTS:

There were highly significant increases in the plasma levels of

IL-6, TNF-alpha and TGF-beta. Increases seen with IL-10 and IL-1

beta were not significant. Plasma CRP levels were unchanged.

CONCLUSION: VNS is associated with marked peripheral increases in

pro- and anti-inflammatory circulating cytokines. Such changes are

unlikely to be non-specific inflammatory reactions, reflected by CRP

levels. In view of gathering evidence supporting a role for the

immune system in modulating affect, as well as seizure activity,

these effects of VNS may be therapeutically relevant. Copyright ©

2005 S. Karger AG, Basel.

PMID: 16166810 [PubMed - in process]

------------------------------------------------------------------------

*4: *J Neurosurg. <javascript:AL_get(this, 'jour', 'J Neurosurg.');>

2005 Mar;102(2 Suppl):213-7. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16156232>

Links <javascript:PopUpMenu2_Set(Menu16156232);>

*Vagus nerve stimulation for induced spinal cord seizures: insights

into seizure cessation.*

*Tubbs RS*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Tubb\

s+RS%22%5BAuthor%5D>,

*Killingsworth CR*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Kill\

ingsworth+CR%22%5BAuthor%5D>,

*Rollins DL*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Roll\

ins+DL%22%5BAuthor%5D>,

* WM*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Smit\

h+WM%22%5BAuthor%5D>,

*Ideker RE*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Idek\

er+RE%22%5BAuthor%5D>,

*Wellons JC 3rd*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Well\

ons+JC+3rd%22%5BAuthor%5D>,

*Blount JP*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Blou\

nt+JP%22%5BAuthor%5D>,

*Oakes WJ*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Oake\

s+WJ%22%5BAuthor%5D>.

Department of Cell Biology, Division of Pediatric Neurosurgery,

University of Alabama at Birmingham, Alabama 35233, USA.

richard.tubbs@...

OBJECT: Vagus nerve stimulation is known to decrease the frequency,

duration, and intensity of some types of intracranial seizures in

both humans and animals. Although many theories abound concerning

the mechanism for this action, the true cause remains speculative.

To potentially elucidate a pathway in which vagus nerve stimulation

aborts seizure activity, seizures were initiated not in the cerebral

cortex but in the spinal cord and then vagus nerve stimulation was

performed. METHODS: Ten pigs were anesthetized and placed in the

lateral position, and a small laminectomy was performed in the

lumbar region. Topical penicillin, a known epileptogenic drug to the

cerebral cortex and spinal cord, was applied to the dorsal surface

of the exposed cord. With the exception of two animals that were

used as controls, once seizure activity was discernible via motor

convulsion or increased electrical activity the left vagus nerve,

which had been previously isolated in the neck, was stimulated.

Following multiple stimulations of the vagus nerve and with seizure

activity confirmed, the cord was transected in the midthoracic

region and vagus nerve stimulation was performed. Vagus nerve

stimulation resulted in cessation of spinal cord seizure activity in

all (87.5%) but one experimented animal. Transection of the spinal

cord superior to the site of seizure induction resulted in the

ineffectiveness of vagus nerve stimulation to cause cessation of

seizure activity in all study animals. CONCLUSIONS: The effects of

vagus nerve stimulation on induced spinal cord seizures involve

descending spinal pathways. The authors believe that this experiment

is the first to demonstrate that spinal cord neuronal hyperactivity

can be suppressed by stimulation of a cranial nerve. These data may

aid in the development of alternative mechanisms for electrical

stimulation in patients with medically intractable seizures. Further

studies are now necessary to isolate which specific tracts, nuclei,

and neurotransmitters are involved in this process.

PMID: 16156232 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*5: *Epileptic Disord. <javascript:AL_get(this, 'jour', 'Epileptic

Disord.');> 2005 Sep;7 Suppl 1:22-6. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16120490>

Links <javascript:PopUpMenu2_Set(Menu16120490);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3050 & uid=16120490 & db=\

pubmed & url=http://www.john-libbey-eurotext.fr/medline.md?issn=1294-9361 & vol=7%20\

Suppl%201 & iss= & page=22>

*VNS Therapy versus the latest antiepileptic drug.*

*Ben-Menachem E*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Ben%\

2DMenachem+E%22%5BAuthor%5D>,

*A French J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22A+Fr\

ench+J%22%5BAuthor%5D>.

Department of Clinical Neuroscience, Sahlgren University Hospital,

Sweden.

Pro AED: The central issue in medical decision-making is

risk-benefit assessment. Surgery of any type is still considered to

be a major undertaking. To warrant these risks, the patient has a

right to expect that they have a greater chance of a good outcome

with an invasive therapy than with a non-invasive one. The main

question is when, if ever, this becomes the case when comparing

implantation of a VNS Therapy System versus adding an antiepileptic

drug (AED)? After the first drug? The second? After all AEDs have

failed? To date, no randomized trial comparing the addition of an

AED against vagus nerve stimulation (VNS Therapy) has been

undertaken, although several are currently being contemplated.

Without this information, it is more difficult to make a case for

early implementation of VNS Therapy. Unfortunately, few data are

available regarding the potential for patients to become

seizure-free after implantation of a VNS Therapy System. Another

issue is side effects. It is important to remember that VNS Therapy

also produces adverse events, albeit very different in character

than those associated with AEDs, to which physicians have become

accustomed. These include cough, dyspnea, pharyngitis, voice

alteration and sleep apnea. A less frequently discussed, potentially

negative consequence of VNS Therapy relates to the ability to obtain

imaging of the patient. Patients who have undergone VNS Therapy

System implantation are not candidates for imaging of the chest,

breast, or abdomen. A second issue is that imaging of the brain can

only be performed with MRI scanners that meet certain requirements,

and as MRI technology develops, scanners meeting these requirements

may become harder to find. However, to summarize, VNS Therapy is an

excellent and useful treatment choice. Fortunately, the choice

between AEDs and VNS Therapy is not an " either/or " decision. Each

has a role in the treatment of patients with epilepsy, and the

advantages and disadvantages of each should be kept in

perspective.Pro VNS Therapy: VNS Therapy is no longer a new

treatment for patients with refractory epilepsy. The first implant

was performed in l988, and since then more than 30,000 patients have

received this therapy. It is no longer considered an unusual or

dangerous procedure, but it is still used almost exclusively for

refractory epilepsy patients and it has not been generally accepted

for use as a first line or even second line therapy. However,

compared to the new AEDs, VNS Therapy has similar efficacy results

in clinical trials and in many epilepsy syndromes and the long-term

efficacy results are even more positive, with continued improvement

in seizure reduction for up to two years. Two of the major reasons

for not using VNS Therapy early are that it is a surgical procedure,

and its safety during MRI procedures, especially with 3 Tesla, has

not yet been elucidated. The safety profile of VNS Therapy is very

favorable; the side effects being totally different from those seen

with AEDs. The most important aspects are that there have been no

pharmacological interactions, cognitive or sedative side effects

reported, and it is safe for use in all age groups. Side effects are

restricted to local irritation, hoarseness, coughing and, in a few

cases, swallowing difficulties when the stimulator is on, but these

tend to disappear with time. No idiosyncratic side effect has

emerged during the 16 years of use. Compliance is guaranteed. The

cost of the implantation of the VNS Therapy System, when spread out

over 8 years (battery life), is actually less than the cost of using

a new AED over an eight-year period, and real savings as regards

hospital costs due to seizures can be expected.

PMID: 16120490 [PubMed - in process]

------------------------------------------------------------------------

*6: *Semin Pediatr Neurol. <javascript:AL_get(this, 'jour', 'Semin

Pediatr Neurol.');> 2005 Jun;12(2):106-13. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16114176>

Links <javascript:PopUpMenu2_Set(Menu16114176);>

*Nonpharmacological treatment options for epilepsy.*

*Sheth RD*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Shet\

h+RD%22%5BAuthor%5D>,

*Stafstrom CE*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Staf\

strom+CE%22%5BAuthor%5D>,

*Hsu D*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Hsu+\

D%22%5BAuthor%5D>.

Department of Neurology, University of Wisconsin, Madison, Madison,

WI 53792-5132, USA. sheth@...

Approximately one third of children with epilepsy have persistent

seizures despite trials of multiple antiepileptic medications. For

some of these patients, epilepsy surgery may provide freedom from

seizures. However, in many cases, epilepsy surgery is not a viable

treatment option. Nonpharmacological approaches are a useful adjunct

to help manage seizures in these children. This review examines the

role of vagus nerve stimulation, the ketogenic diet, and various

forms of EEG biofeedback therapy in children with intractable

epilepsy. Although the mechanism of action is not known precisely

for any of these adjunctive therapies, they add an important and

evolving dimension to the management of difficult to control

epilepsy in children. In addition, pyridoxine-dependent seizures are

discussed as an example of an etiology of refractory seizures that

responds well to replacement therapy.

Publication Types:

* Review <javascript:AL_get(this, 'ptyp', 'Review');>

* Review, Tutorial <javascript:AL_get(this, 'ptyp', 'Review,

Tutorial');>

PMID: 16114176 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*7: *Seizure. <javascript:AL_get(this, 'jour', 'Seizure.');> 2005 Aug 9;

[Epub ahead of print] Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16098769>

Links <javascript:PopUpMenu2_Set(Menu16098769);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048 & uid=16098769 & db=\

pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S1059-1311%2805%2900123-8\

>

*Long term effects on epileptiform activity with vagus nerve

stimulation in children.*

*Hallbook T*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Hall\

book+T%22%5BAuthor%5D>,

*Lundgren J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Lund\

gren+J%22%5BAuthor%5D>,

*Blennow G*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Blen\

now+G%22%5BAuthor%5D>,

*Stromblad LG*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Stro\

mblad+LG%22%5BAuthor%5D>,

*Rosen I*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Rose\

n+I%22%5BAuthor%5D>.

Department of Paediatrics, University Hospital, SE-221 85 Lund, Sweden.

PURPOSE:: We report long-term effects of vagus nerve stimulation

(VNS) on epileptiform activity in 15 children, and how these changes

are related to activity stage and to clinical effects on seizure

reduction, seizure severity (NHS3) and quality of life (QOL).

METHODS:: Initially, and after 3 and 9 months of VNS-treatment, 15

children were investigated with 24h ambulatory EEG monitoring for

spike detection. The number of interictal epileptiform discharges

(IEDs) and the inter spike intervals (ISIs) were analysed during 2h

in the awake state, and 1h of rapid eye movement (REM)-, spindle-

and delta-sleep, respectively. Total number and duration of

electrographic seizure episodes were also analysed. RESULTS:: At 9

months the total number of IEDs was significantly reduced (p=0.04).

There was a tendency of reduction in all activity stages, and

significantly so in delta-sleep (p=0.008). Total electrographic

seizure number was significantly reduced in the 24h EEG at 3 and 9

months (p=0.03, 0.05). There was a significant concordance in

direction of changes in epileptiform activity and electrographic

seizures at 9 months (p=0.04). Concordance in direction of changes

was seen in 9 of 15 children between clinical seizures and IED

(p>0.3), in 10 of 15 children between QOL and IED (p=0.3) and in 8

of 15 children between NHS3 and IED (p>0.3). There was no direct

correlation between the extent of improvement in these clinical data

and the degree of spike reduction. CONCLUSION:: This study shows

that VNS reduces IEDs especially in REM and delta sleep, as well as

the number of electrographic seizures. It also shows a concordance

between reduction in IEDs and electrographic seizures.

PMID: 16098769 [PubMed - as supplied by publisher]

------------------------------------------------------------------------

*8: *Epilepsy Curr. <javascript:AL_get(this, 'jour', 'Epilepsy Curr.');>

2004 Nov-Dec;4(6):215-22. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16059506>

Links <javascript:PopUpMenu2_Set(Menu16059506);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3494 & uid=16059506 & db=\

pubmed & url=http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed & pubmedid=\

16059506>

*Dietary approaches to epilepsy treatment: old and new options on

the menu.*

*Stafstrom CE*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Staf\

strom+CE%22%5BAuthor%5D>.

Department of Neurology, University of Wisconsin, Madison, USA.

stafstrom@...

Dietary therapies represent a potentially valuable adjunct to other

epilepsy treatments, such as anticonvulsant medications, epilepsy

surgery, and vagus nerve stimulation. Although the ketogenic diet

(high fat, adequate protein, low carbohydrate) is the most

well-established dietary therapy for epilepsy, other possible

approaches include the Atkins diet (high fat, high protein, low

carbohydrate), a diet enriched in polyunsaturated fatty acids, or

overall restriction of calorie intake. This review discusses the

current clinical status of each of these dietary approaches and

suggests possible mechanisms by which they might suppress neuronal

hyperexcitability and seizures.

PMID: 16059506 [PubMed]

------------------------------------------------------------------------

*9: *Epilepsy Behav. <javascript:AL_get(this, 'jour', 'Epilepsy

Behav.');> 2005 Sep;7(2):182-9. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16054872>

Links <javascript:PopUpMenu2_Set(Menu16054872);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048 & uid=16054872 & db=\

pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S1525-5050%2805%2900219-2\

>

*Transcranial magnetic stimulation treatment for epilepsy: can it

also improve depression and vice versa?*

*Fregni F*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Freg\

ni+F%22%5BAuthor%5D>,

*Schachter SC*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Scha\

chter+SC%22%5BAuthor%5D>,

*Pascual-Leone A*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Pasc\

ual%2DLeone+A%22%5BAuthor%5D>.

Department of Neurology, Beth Israel Deaconess Medical Center,

Harvard Medical School, Boston, USA. ffregni@...

Comorbidity with depression is an important determinant of the

quality of life for patients with epilepsy. Antidepressant

medications can effectively treat depression in epileptic patients,

but drug-drug interactions and epileptogenic effects of these drugs

pose therapeutic challenges. The mood-stabilizing effects of

antiepileptic medications may not be sufficient to treat depression.

Therefore, treatments that alleviate the burden of depression

without increasing seizure risk or, better yet, with the possibility

of improving seizure control are worth exploring. Neuroimaging

techniques, such as functional magnetic resonance imaging, are

providing novel insights into the pathophysiology of depression in

epilepsy. For example, there appears to be prominent brain

prefrontal hypoactivity, which may be sustained by the hyperactivity

of the seizure focus. If so, neuromodulatory approaches that

suppress epileptic focus hyperactivity and concurrently enhance

prefrontal activity may be ideally suited. Indeed, vagus nerve

stimulation has been shown to yield simultaneous antiseizure and

mood effects. Another neuromodulatory technique, transcranial

magnetic stimulation (TMS), can also modulate brain activity, but in

a noninvasive, painless, and focal manner. Depending on the

stimulation parameters, it is possible to enhance or reduce activity

in the targeted brain region. Furthermore, TMS has been shown to be

effective in treating depression, and preliminary data suggest that

this treatment may also be effective for epilepsy treatment. This

article reviews these data and explores further the question of

whether depression and epilepsy can be simultaneously treated with

TMS for optimal therapeutic impact.

PMID: 16054872 [PubMed - in process]

------------------------------------------------------------------------

*10: *Surg Neurol. <javascript:AL_get(this, 'jour', 'Surg Neurol.');>

2005 Aug;64(2):170-3. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=16051017>

Links <javascript:PopUpMenu2_Set(Menu16051017);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048 & uid=16051017 & db=\

pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S0090-3019%2804%2900944-9\

>

*Control of refractory status epilepticus precipitated by

anticonvulsant withdrawal using left vagal nerve stimulation: a case

report.*

*Patwardhan RV*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Patw\

ardhan+RV%22%5BAuthor%5D>,

*Dellabadia J Jr*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Dell\

abadia+J+Jr%22%5BAuthor%5D>,

*Rashidi M*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Rash\

idi+M%22%5BAuthor%5D>,

*Grier L*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Grie\

r+L%22%5BAuthor%5D>,

*Nanda A*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Nand\

a+A%22%5BAuthor%5D>.

Department of Neurosurgery, Louisiana State University Health

Sciences Center in Shreveport, Shreveport, LA 71130-3932, USA.

OBJECTIVE: To describe a case of left vagal nerve stimulation (VNS)

resulting in immediate cessation of status epilepticus (SE) with

good neurological outcome. CASE DESCRIPTION: A 30-year-old man with

medically intractable seizures including episodes of SE was

successfully treated using left VNS. After requiring discontinuation

of phenytoin, valproic acid, carbamazepine, and topiramate because

of severe allergic reactions resembling s- syndrome,

the patient required pentobarbital coma along with phenobarbital,

tiagabine, and levetiracetam for seizure frequency reduction. He

underwent left vagal nerve stimulator placement after nearly 9 days

of barbiturate-induced coma, with stimulation initiated in the

operating room. On the following day, electroencephalography

revealed resolution of previously observed periodic lateral

epileptiform discharges and the patient was free of seizures.

Prestimulation seizure frequency was recorded at 59 times a day,

with some seizures enduring 45 minutes despite barbiturate coma.

Poststimulation, the patient has been free of seizures for 19 days

and is presently taking only levetiracetam and phenobarbital, from

which he continues to be successfully weaned without seizures. He is

awake, alert, and can recall events leading up to his seizures, with

good long-term memory and residual left upper extremity and lower

extremity weakness. CONCLUSION: This case illustrates the role of

left vagal stimulation in the treatment of SE and otherwise

medically intractable seizures caused by allergic reactions. To our

knowledge, this is the first case in the world literature for adults

reporting cessation of SE after VNS. Another case with a similar

improvement has been reported in the pediatric population.

Publication Types:

* Case Reports <javascript:AL_get(this, 'ptyp', 'Case Reports');>

PMID: 16051017 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*11: *Neurology. <javascript:AL_get(this, 'jour', 'Neurology.');> 2005

Jun 28;64(12 Suppl 3):S2-11. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15994220>

Links <javascript:PopUpMenu2_Set(Menu15994220);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051 & uid=15994220 & db=\

pubmed & url=http://www.neurology.org/cgi/pmidlookup?view=long & pmid=15994220>

*Current treatments of epilepsy.*

*Nadkarni S*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Nadk\

arni+S%22%5BAuthor%5D>,

*LaJoie J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22LaJo\

ie+J%22%5BAuthor%5D>,

*Devinsky O*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Devi\

nsky+O%22%5BAuthor%5D>.

Comprehensive Epilepsy Center, NYU School of Medicine, 403 East 34th

Street, 4th Floor, New York, NY 10016, USA. siddhu@...

Medical therapy is the mainstay for epilepsy, with most patients

well controlled on a single antiepileptic drug (AED). In this

non-refractory group, many patients have medication side effects and

occasional seizures. Approximately 30% of patients with partial

epilepsy and 25% of patients with generalized epilepsy are not well

controlled on medications. These patients are often receiving

multiple AEDs, with disabling seizures and side effects. Although

second-generation AEDs are safer and better tolerated than the older

AEDs, there are scant data to support significant advantages in

efficacy. In VA studies with older AEDS, therapy with two AEDs

improved seizure control in 40% of patients but seizure freedom was

achieved in only 9%. A meta-analysis of the second-generation AEDs

used as adjunctive therapies shows that 12% to 29% of patients had a

50% or greater reduction in seizure frequency. Surgery and the vagus

nerve stimulator provide important therapeutic options in patients

whose seizures are not controlled by AEDs. Special considerations

about epilepsy care must be made in pediatric populations, those

with developmental delays, women, and the elderly.

Publication Types:

* Review <javascript:AL_get(this, 'ptyp', 'Review');>

PMID: 15994220 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*12: *Expert Opin Investig Drugs. <javascript:AL_get(this, 'jour',

'Expert Opin Investig Drugs.');> 1997 Oct;6(10):1327-35. Related

Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15989504>

Links <javascript:PopUpMenu2_Set(Menu15989504);>

*Vagus nerve stimulation: current status and clinical applications.*

*Schachter SC*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Scha\

chter+SC%22%5BAuthor%5D>.

Comprehensive Epilepsy Program, Department of Neurology, Beth Israel

Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215,

USA. Sschacht@...

Despite the recent introduction of new anti-epileptic drugs (AEDs),

many patients with epilepsy, especially those with partial-onset

seizures, continue to have seizures that are refractory to

pharmacotherapy. Other patients are unable to tolerate the

side-effects of AEDs given singly or in combination. Cerebral

resective surgery may be an option for a sub-group of these

patients; however, many patients with refractory partial epilepsy

are not optimal candidates for epilepsy surgery. Consequently, the

introduction of left vagus nerve stimulation (VNS) for those

patients who have been afflicted by seizures or medication

side-effects has opened up a new, non-pharmacological approach to

epilepsy treatment. The mechanism of action of VNS is uncertain. VNS

exerts an anticonvulsant effect in a variety of animal seizure

models; has no effect on hepatic metabolic processes, serum

concentrations of AEDS, or laboratory values; and has no clinically

significant effect on vagally-mediated physiological processes. VNS

is safe and well-tolerated in patients with long-standing,

medically-refractory, partial-onset epilepsy. Adverse effects are

usually mild to moderate in severity and related to stimulation, and

almost always resolve with adjustment in stimulation settings.

Controlled studies of patients on AED therapy show that adjunctive

VNS is effective for partial-onset seizures when given every 5 min

for 30 s intervals. Results of studies in paediatric patients are

encouraging.

PMID: 15989504 [PubMed]

------------------------------------------------------------------------

*13: *Epilepsia. <javascript:AL_get(this, 'jour', 'Epilepsia.');>

2005;46 Suppl 5:94-7. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15987260>

Links <javascript:PopUpMenu2_Set(Menu15987260);>

*The acute and chronic effect of vagus nerve stimulation in genetic

absence epilepsy rats from Strasbourg (GAERS).*

*Dedeurwaerdere S*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Dede\

urwaerdere+S%22%5BAuthor%5D>,

*Vonck K*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Vonc\

k+K%22%5BAuthor%5D>,

*Van Hese P*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Van+\

Hese+P%22%5BAuthor%5D>,

*Wadman W*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Wadm\

an+W%22%5BAuthor%5D>,

*Boon P*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Boon\

+P%22%5BAuthor%5D>.

Reference Centre for Refractory Epilepsy and Laboratory for Clinical

and Experimental Neurophysiology, Department of Neurology, Ghent

University Hospital, Ghent, Belgium. Stefanie.Dedeurwaerdere@...

PURPOSE: The aim of this study was to evaluate the efficacy of acute

and chronic vagus nerve stimulation (VNS) in genetic absence

epilepsy rats from Strasbourg (GAERS). This is a validated model for

absence epilepsy, characterized by frequent spontaneous absences

concomitant with spike and wave discharges (SWD) on the EEG.

Although absences are a benign form of seizures, it is conceptually

important to investigate the efficacy of VNS in a controlled study

by using this chronic epilepsy model. METHODS: Both control and

stimulated GAERS were implanted with five epidural EEG electrodes

and a stimulation electrode around the left vagus nerve. In the

first experiment, VNS was given when SWD occurred in the EEG; this

was repeated the next day. A randomized crossover design (n = 8) was

used. In the chronic experiment, GAERS underwent EEG monitoring

during a first baseline week. During the second week, the treated

group (n = 18) received VNS; controls (n = 13), on the other hand,

only underwent EEG recordings. RESULTS: On day 1 of the acute VNS

experiment, the mean duration of the SWD when VNS was applied was

higher than in baseline conditions (p < 0.05). However, on day 2,

there was no difference in mean duration of the SWD. In the chronic

VNS experiment, no statistically significant differences were found

between control and stimulated GAERS. CONCLUSIONS: Acute VNS applied

shortly after the onset of SWD prolonged the mean duration of SWD in

GAERS at least during the first day of VNS. Chronic stimulation

hardly affected SWD in GAERS.

PMID: 15987260 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*14: *Curr Treat Options Neurol. <javascript:AL_get(this, 'jour', 'Curr

Treat Options Neurol.');> 2005 Jul;7(4):261-271. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15967089>

Links <javascript:PopUpMenu2_Set(Menu15967089);>

*Experimental Electrical Stimulation Therapy for Epilepsy.*

*Oommen J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Oomm\

en+J%22%5BAuthor%5D>,

*Morrell M*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Morr\

ell+M%22%5BAuthor%5D>,

*Fisher RS*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Fish\

er+RS%22%5BAuthor%5D>.

Stanford Department of Neurology, Room A343, Stanford Medical

Center, 300 Pasteur Drive, Stanford, CA 94305, USA.

rfisher@....

Electrical stimulation of the nervous system is an attractive

possible therapy for intractable epilepsy, but only stimulation of

the vagus nerve has been subjected to large, controlled, and

completed clinical trials. Controlled trials are in progress for

intermittent cycling stimulation of the anterior nuclei of the

thalamus, and for cortical stimulation at a seizure focus,

responsive to detection of seizure onset. Anecdotal experience has

been gathered with stimulation of cerebellum, centromedian thalamus,

subthalamus, caudate, hippocampus, and brainstem. All stimulation of

the central nervous system for epilepsy must be considered experimental.

PMID: 15967089 [PubMed - as supplied by publisher]

------------------------------------------------------------------------

*15: *Neuropsychobiology. <javascript:AL_get(this, 'jour',

'Neuropsychobiology.');> 2005;51(4):265-8. Epub 2005 May 18. Related

Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15905632>

Links <javascript:PopUpMenu2_Set(Menu15905632);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3030 & uid=15905632 & db=\

pubmed & url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext & file=N\

PS2005051004265>

*Cerebral blood flow during vagus nerve stimulation--a transcranial

Doppler study.*

*Neu P*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Neu+\

P%22%5BAuthor%5D>,

*Heuser I*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Heus\

er+I%22%5BAuthor%5D>,

*Bajbouj M*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Bajb\

ouj+M%22%5BAuthor%5D>.

Department of Psychiatry and Psychotherapy, Charite Berlin, Campus

lin, Eschenallee 1, DE-14050 Berlin, Germany.

peter.neu@...

BACKGROUND AND OBJECTIVES: Vagus nerve stimulation (VNS) is an

approved treatment of partial onset seizures and has recently shown

antidepressant effects in patients with treatment-resistant

depression. This study was conducted to investigate whether acute

VNS has an influence on cerebral blood flow (CBF) in humans.

METHODS: This investigation was designed as an add-on study. In 10

patients with an implanted stimulator who participated in a

multicenter clinical trial to evaluate the efficacy of VNS in

depression, CBF was investigated by functional transcranial Doppler

at baseline (before the stimulator was turned on for the first time)

and during stimulation with three different stimulation intensities

in a randomized order. RESULTS: Immediately after every increase of

the current, CBF velocity showed a nonsignificant increase.

Otherwise, no change of CBF above standard deviation could be

registered. CONCLUSION: Acute VNS does not have an influence on CBF

velocity in depressive patients. Copyright © 2005 S. Karger AG, Basel.

Publication Types:

* Clinical Trial <javascript:AL_get(this, 'ptyp', 'Clinical

Trial');>

* Multicenter Study <javascript:AL_get(this, 'ptyp',

'Multicenter Study');>

* Randomized Controlled Trial <javascript:AL_get(this, 'ptyp',

'Randomized Controlled Trial');>

PMID: 15905632 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*16: *Br Med Bull. <javascript:AL_get(this, 'jour', 'Br Med Bull.');>

2005 Apr 21;72:135-48. Print 2004. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15845748>

Links <javascript:PopUpMenu2_Set(Menu15845748);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051 & uid=15845748 & db=\

pubmed & url=http://bmb.oxfordjournals.org/cgi/pmidlookup?view=long & pmid=15845748>

*Advances in epilepsy.*

*Kelso AR*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Kels\

o+AR%22%5BAuthor%5D>,

*Cock HR*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Cock\

+HR%22%5BAuthor%5D>.

Epilepsy Group, Centre for Clinical Neurosciences, St 's

University of London, UK.

Advances in understanding of both the causes and consequences of

epilepsy have been paralleled by a number of recent reports and

clinical guidelines highlighting the complexities involved in both

diagnosing and treating epilepsy. We review recent developments,

including comments on the evolution of clinical guidelines,

anti-epileptic drugs, epilepsy surgery and new treatment approaches

in development. Epilepsy genetics and emerging evidence on

mechanisms of drug resistance in epilepsy will also be discussed.

Issues with respect to pregnancy and epilepsy are considered,

together with more recently identified dilemmas including bone

health in epilepsy and whether seizures themselves cause brain

damage. Imaging in epilepsy has recently been reviewed elsewhere,

and will not be discussed.

Publication Types:

* Review <javascript:AL_get(this, 'ptyp', 'Review');>

* Review, Tutorial <javascript:AL_get(this, 'ptyp', 'Review,

Tutorial');>

PMID: 15845748 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*17: *Epilepsy Behav. <javascript:AL_get(this, 'jour', 'Epilepsy

Behav.');> 2005 May;6(3):417-23. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15820352>

Links <javascript:PopUpMenu2_Set(Menu15820352);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048 & uid=15820352 & db=\

pubmed & url=http://linkinghub.elsevier.com/retrieve/pii/S1525-5050%2805%2900039-9\

>

*Vagus nerve stimulation therapy: 2-year prospective open-label

study of 40 subjects with refractory epilepsy and low IQ who are

living in long-term care facilities.*

*Huf RL*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Huf+\

RL%22%5BAuthor%5D>,

*Mamelak A*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Mame\

lak+A%22%5BAuthor%5D>,

*Kneedy-Cayem K*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Knee\

dy%2DCayem+K%22%5BAuthor%5D>.

Epilepsy and Brain Mapping Program, Huntington Memorial Hospital,

Pasadena, CA, USA. karacayem@...

Treating seizures among patients with mental

retardation/developmental disabilities (MR/DD) is difficult owing in

large part to the presence of additional comorbidities and the

resulting need for polytherapy. Therefore, a nonpharmacological

treatment option is needed for this population. This prospective,

open-label study documented the long-term outcome of 40 low-IQ (<70)

patients living in long-term care facilities who received vagus

nerve stimulation (VNS) therapy for pharmacoresistant epilepsy.

Subjects were seen every 1 to 3 months by their neurologist (R.H.).

Seizure frequency, antiepileptic medication, and quality-of-life

information were documented preimplantation and quarterly thereafter

through 2 years. The surgery and therapy were well tolerated.

Seizures were reduced by at least 50% for 11 subjects. Antiepileptic

medications were reduced from 3.3 per subject at baseline to an

average of 2.3 per subject after 2 years. According to caregiver

reports, overall quality of life improved for the majority of

subjects; also, using the Client Development Evaluation Report

(CDER), statistically significant improvements were reported at both

1 and 2 years in attention span, word usage, clarity of speech,

standing balance, washing dishes, and household chores. VNS is a

viable treatment option for low-IQ patients with pharmacoresistant

epilepsy who are living in long-term care facilities.

Publication Types:

* Clinical Trial <javascript:AL_get(this, 'ptyp', 'Clinical

Trial');>

PMID: 15820352 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*18: *Actas Esp Psiquiatr. <javascript:AL_get(this, 'jour', 'Actas Esp

Psiquiatr.');> 2005 Mar-Apr;33(2):130-4. Related Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15768321>

Links <javascript:PopUpMenu2_Set(Menu15768321);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4287 & uid=15768321 & db=\

pubmed & url=http://www.arsxxi.com/Revistas/mostrararticulo.php?idarticulo=5111011\

9>

*[Vagus nerve stimulation and psychosis. A single case report]*

[Article in Spanish]

*Adan J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Adan\

+J%22%5BAuthor%5D>,

*Escosa M*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Esco\

sa+M%22%5BAuthor%5D>,

*Ayuso-Mateos JL*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Ayus\

o%2DMateos+JL%22%5BAuthor%5D>.

Servicio de Psiquiatria, Hospital Universitario de La Princesa,

Universidad Autonoma de Madrid. jaumeson@...

The appearance of behavioral disorders in the context of a decrease

in the number of seizures in epileptic patients is a fact that was

already described in Landolt's theory of forced normalization in the

middle of the XX century. Through this clinical case, we propose

several mechanisms that aim to give a general explanation to the

physiopathology of this condition. Among them, the theory which

suggests increased alertness as a result of inhibitory mechanisms

secondary to a long lasting epileptic condition stands out. In

addition, we consider the possibility that left vagus nerve

stimulation (VNS), a procedure used as a second line treatment in

epileptic patients refractory to multiple drug therapy, may cause an

inhibitory reaction of similar characteristics as the previously

described, and could therefore lead to different psychiatric

disorders. Lastly, we bring up several alternatives that will try to

throw some light on the physiopathological condition that leads to

the chronification of this disease, the theory regarding a cognitive

deterioration associated to the appearance of negative symptoms in

patients with temporal lobe epilepsy standing out.

Publication Types:

* Case Reports <javascript:AL_get(this, 'ptyp', 'Case Reports');>

PMID: 15768321 [PubMed - indexed for MEDLINE]

------------------------------------------------------------------------

*19: *J Neurol Neurosurg Psychiatry. <javascript:AL_get(this, 'jour', 'J

Neurol Neurosurg Psychiatry.');> 2005 Mar;76(3):384-9. Related

Articles,

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Display & dopt=pubmed\

_pubmed & from_uid=15716532>

Links <javascript:PopUpMenu2_Set(Menu15716532);>

Click here to read

<http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051 & uid=15716532 & db=\

pubmed & url=http://jnnp.bmjjournals.com/cgi/pmidlookup?view=long & pmid=15716532>

*Vagus nerve stimulation: predictors of seizure freedom.*

*Janszky J*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Jans\

zky+J%22%5BAuthor%5D>,

*Hoppe M*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Hopp\

e+M%22%5BAuthor%5D>,

*Behne F*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Behn\

e+F%22%5BAuthor%5D>,

*Tuxhorn I*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Tuxh\

orn+I%22%5BAuthor%5D>,

*Pannek HW*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Pann\

ek+HW%22%5BAuthor%5D>,

*Ebner A*

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & term=%22Ebne\

r+A%22%5BAuthor%5D>.

Epilepsie-Zentrum Bethel, Mara Krankenhaus, Maraweg 21, Bielefeld

33617, Germany.

OBJECTIVES: To identify predictive factors for the seizure-free

outcome of vagus nerve stimulation (VNS). METHODS: All 47 patients

who had undergone VNS implantation at one centre and had at least

one year of follow up were studied. They underwent complete

presurgical evaluation including detailed clinical history, magnetic

resonance imaging, and long term video-EEG with ictal and interictal

recordings. After implantation, adjustment of stimulation parameters

and concomitant antiepileptic drugs were at the discretion of the

treating physician. RESULTS: Mean (SD) age of the patients was 22.7

(11.6) years (range 7 to 53). Six patients (13%) became seizure-free

after the VNS implantation. Only two variables showed a significant

association with the seizure-free outcome: absence of bilateral

interictal epileptiform discharges (IED) and presence of

malformation of cortical development (MCD). Epilepsy duration showed

a non-significant trend towards a negative association with outcome.

By logistic regression analysis, only absence of bilateral IED

correlated independently with successful VNS treatment (p<0.01, odds

ratio = 29.2 (95% confidence interval, 2.4 to 353)). Bilateral IED

(independent or bilateral synchronous) was found in one of six

seizure-free patients and in 33 of 41 non-seizure-free patients.

When bilateral IED were absent, the sensitivity for seizure-free

outcome was 0.83 (0.44 to 0.97), and the specificity was 0.80 (0.66

to 0.90). CONCLUSIONS: Bilateral IED was independently associated

with the outcome of VNS. These results are preliminary because they

were based on a small patient population. They may facilitate

prospective VNS studies enrolling larger numbers of patients to

confirm the results.

Publication Types:

* Clinical Trial <javascript:AL_get(this, 'ptyp', 'Clinical

Trial');>

PMID: 15716532

Liz Mumper wrote:

> Hi, :

>

> Noted ref #247 in the citation list: Park YD. The effects of vagus

> nerve stimulation therapy on pts with intractable seizures and L-K or

> autism. Epilepsy Behav 2003 June

>

> Have a patient who wants to try it. Do you have other references at

> your fingertips?

>

> Liz

>

>

>

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...